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Food combinations have been associated with lower incidence of Alzheimer’s disease. We hypothesized
that a combination whole-food diet containing freeze-dried ﬁsh, vegetables, and fruits would improve
cognitive function in TgCRND8 mice by modulating brain insulin signaling and neuroinﬂammation.
Cognitive function was assessed by a comprehensive battery of tasks adapted to the Morris water maze.
Unexpectedly, a “Diet  Transgene” interaction was observed in which transgenic animals fed the whole-
food diet exhibited even worse cognitive function than their transgenic counterparts fed the control diet
on tests of spatial memory (p < 0.01) and strategic rule learning (p ¼ 0.034). These behavioral deﬁcits
coincided with higher hippocampal gene expression of tumor necrosis factor-a (p ¼ 0.013). There were
no differences in cortical amyloid-b peptide species according to diet. These results indicate that a dietary
proﬁle identiﬁed from epidemiologic studies exacerbated cognitive dysfunction and neuroinﬂammation
in a mouse model of familial Alzheimer’s disease. We suggest that normally adaptive cellular responses
to dietary phytochemicals were impaired by amyloid-beta deposition leading to increased oxidative
stress, neuroinﬂammation, and behavioral deﬁcits.
 2015 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction
The availabilityof transgenic animalmodels ofAlzheimer’s disease
(AD) has permitted investigations into the impact of nutrients and
other compounds isolated from foods on disease-related neuropa-
thology, particularly amyloid-beta peptide (Ab), and behavioral deﬁ-
cits. Among the most studied compounds are docosahexaenoic acid
(DHA), antioxidant vitamins, and certain dietary phytochemicals
which have been shown to be beneﬁcial in many (Calon et al., 2004;
Frautschy et al., 2001; Lee et al., 2012b; Murakami et al., 2011; Rezai-
Zadeh et al., 2008;Wanget al., 2008), but not all cases (Arendashet al.,
2007). These beneﬁcial ﬁndings have been attributed to control of
oxidative stress and, despite concerns over lack of direct in vivo evi-
dence (Orr et al., 2013), neuroinﬂammation. However, it is becomingBY-NC-ND license (http://
te, Baycrest Health Sciences,
Canada. Tel.: þ1 416 785
. Greenwood).
Published by Elsevier Inc. All righincreasingly evident that dietary compounds, especially DHA and
phytochemicals, exert a pleiotropic effect bymodulating cell signaling
pathways that impact on additional mechanisms like synaptic plas-
ticity and the enzymatic processing of Ab (Davinelli et al., 2012;
Frautschy and Cole, 2010; Grimm et al., 2011; Zhao et al., 2011).
Many of these cell signaling changes involve regulators of cellular
energy homeostasis and growth that are also commonly modulated
by insulin. Interestingly, impaired neuronal insulin signaling is a
prominent feature of AD that has been linked to disease severity, Ab
deposition, and degree of cognitive dysfunction (Bomﬁm et al., 2012;
Craft et al., 2013; de la Monte, 2012; Talbot et al., 2012).
Despite the diversity of potential mechanisms and promising
results in animal models, clinical trials have found limited or no
beneﬁts of single nutrients like antioxidant vitamins (Galasko et al.,
2012; Sano et al., 1997) and DHA (Freund-Levi et al., 2006; Quinn
et al., 2010) in AD. This mismatch between basic and clinical
studies has led some to speculate that background diet may be an
important determinant of intervention success such that single
nutrient supplementation is unlikely to beneﬁt those with replete
diets, or conversely, that supplementation with a single nutrientts reserved.
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quality (Morris, 2012). The recognition that whole foods provide a
wide array of compounds that may interact to produce synergistic
effects has led to the interest in the role that food combinations or
diet quality may play in preventing ADwith some positive results in
the epidemiologic literature (Gu et al., 2010; Scarmeas et al., 2006).
The present study is the ﬁrst in a systematic investigation of the
impact of a combined whole-food diet (WFD) on cognitive function
and Ab deposition in a transgenic mouse model of AD. Given the
evidence surrounding their efﬁcacy from epidemiologic and basic
studies, food sources of DHA, antioxidant vitamins, and phytoche-
micalsdnamely freeze-dried ﬁsh, fruits, and vegetablesdwere
targeted. Because these dietary compounds have been shown to
inﬂuence brain insulin signaling and neuroinﬂammation, cerebral
gene expression of these pathways was also determined. The
following tests of learning and memory were administered to
measure cognitive functions known to be affected in AD: (1) spatial
memory (Morris, 1984) inwhich distal environmental cues are used
to ﬁnd a submerged platform. This test is sensitive to impairment
within the hippocampus, a subcortical structure that is widely
implicated in the memory loss reliably seen early in AD; (2)
nonmatching-to-sample (NMTS) which requires that animals
differentiate between sample and test stimuli and select one ac-
cording to a learned rule. NMTS and similar rule-learning tasks
incorporate conditional and working memory components that are
critical for many types of problem solving under the control of the
prefrontal cortex (Moscovitch and Winocur, 1995). These abilities,
along with the integrity of the frontal lobes, are increasingly
compromised in AD as the disease progresses; and (3) brightness
discrimination learning in which mice must discriminate between
black and white stimuli to ﬁnd the platform. This task is believed to
depend on the caudate nucleus and related striatal structures
(McDonald et al., 1999), a brain system that is affected in the later
stages of AD. Our working hypothesis was that the WFD containing
ﬁsh, vegetables, and fruits would beneﬁcially inﬂuence cognitive
performance and Ab deposition through modulation of brain in-
sulin signaling and neuroinﬂammation.
2. Methods
2.1. Mice and diets
TgCRND8mice (Chishti et al., 2001) overexpressingmutations in
the human APP gene (KM670/671NL, V717F) and maintained on a
mixed C3H/C57 outbred background were obtained courtesy of the
Tanz Centre for Research in Neurodegenerative Diseases. Animals
were housed 3e4 per cage (L: 29 cm, W: 18 cm, H: 12 cm) in a fa-
cility with controlled temperature (21 C), humidity (40%), and light
cycle (12 hour light and/or dark). Mice had ad libitium access to
either the WFD or control diets fromweaning (aged 3 weeks) until
sacriﬁce at 7 months of age (Harlan Teklad, Madison, WI, USA; see
Supplementary Table 1 for detailed composition). The WFD con-
tained skinless freeze-dried Atlantic salmon (prepared by Guelph
Food Technology Centre, Guelph, Ontario, Canada) and a pro-
prietary mixture of powdered, freeze-dried vegetables and fruits
(BerryGreen, New Chapter, Brattleboro, VT, USA). The 3 most
abundant ingredients of this mixture were spinach, blueberries,
and cruciferous vegetables (kale, cabbage, broccoli, and brussel
sprouts). The total fat content and fatty acid proﬁle of the freeze-
dried salmon was determined by ﬂame-ionized gas chromatog-
raphy as described previously (Reza-Lopez et al., 2009). The total
phenolic content and oxygen radical absorbance capacity expressed
in millimoles of Trolox equivalents (mmolTE) of the fruit and
vegetable mixture were determined by an independent lab
(Brunswick Laboratories, Southborough, MA, USA). Based on theseanalyses, the WFD provided 2.46 mg docosahexaenoic acid (0.246%
wt/wt), 1.10 mg total phenolics, and 0.018 mmolTE per gram of diet.
The control diet was formulated to have the same energy density
(3.8 kcal/g), macronutrient composition (17% fat, 64% carbohydrate,
and 19% protein per kcal of diet), and ﬁber content as theWFD. Corn
oil acted as the main source of dietary fat.
At 4 months of age, mice were transferred to Trent University for
cognitive testing. Testing commenced after a 2-week acclimatiza-
tion period and lasted for an additional 2.5 months. Animals were
sacriﬁced at 7 months of age by pentobarbital overdose. Following
rapid excision, brains were dissected on a cold surface in PBS, ﬂash
frozen in liquid nitrogen, and stored at 80 C.
2.2. Cognitive testing
The spatial memory, NMTS, and brightness discrimination tasks
were administered in a circular pool (130 cm diameter and
approximately 30 cm high), located in the center of a room
(360 cm 360 cm). The pool was ﬁlled withwater rendered opaque
by diluted nontoxic white tempera paint, to a depth of 18 cm and
maintained at room temperature (21 oC). An inverted ﬂower pot
(15 cm high by 10 cm in diameter) with a white surface, situated a
few centimeters below the surface of the water, served as a plat-
form on which the mice could climb to escape the water. A heat
lamp near the pool provided a warm area where mice waited be-
tween trials. Throughout testing, the water was cleaned after each
trial and changed every 2e3 days.
For the spatialmemory and theNMTS tasks, the poolwas divided
into 6 zones of equal size. Swimming patterns of mice were moni-
tored byan overhead video camera connected to a recorder and data
processing system. The system enabled computation of the time
required to ﬁnd and climb on the platform and the time spent in the
platform zone. Records were kept of the animals’ swimming routes
that were used to count errors. For the brightness discrimination
task, the pool was ﬁtted with a T-mazewhosewalls extended 10 cm
above the water surface. The stem of the “T” was 27 cm long. The
horizontal armwas 65 cm longwith slats along thewalls intowhich
black or white panels were inserted. The submerged platform was
located at the end of the panel designated as the positive arm.
These tasks are commonly used in our laboratory to assess the
effects of various types of brain dysfunction on cognitive perfor-
mance inmice (Winocur et al., 2006) and rats (Winocur et al., 2013).
All testing was conducted by a single experimenter who was blind
to the treatment history.
2.2.1. Spatial memory
Initially, mice received 2 days of orientation training, consisting
of 5 trials/day in which mice were placed individually in the pool
and allowed to swim to and climb on the platform, which was
visible a few centimeters above the surface of the liquid. The
location in which the mice were placed in the pool and the location
of the platformwere varied from trial to trial. A trial continued until
the mouse mounted the platform with all 4 paws or until 120 sec-
onds elapsed. Themousewas allowed to remain on the platform for
10 seconds; if it failed to ﬁnd the platform in the allotted time, it
was manually guided to the platform where it was allowed to
remain for 10 seconds. The mouse was then removed and placed in
a clean cage under the heat lamp to await the next trial. The mice
were run in squads of 4e5, allowing for an interval of 2e3 minutes
between trials.
Spatial memory testing began on day 3. The platform was now
below the surface of the water and always located in the center of
the north-east zone of the pool. For each trial, themousewas placed
in the water at the edge of the pool, facing the wall, at a different
location. The starting locations were determined by a semi-random
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was used at least once each day. The starting location was never in
the north-east zone. Trial administration was identical to that fol-
lowed in orientation training, with each trial continuing until the
mouse mounted the platform with all 4 paws, or until 120 seconds
elapsed. As before, the mouse was allowed to remain on the plat-
form for 10 seconds; if it failed to ﬁnd the platform in the allotted
time, it was manually guided to the platform for 10 seconds. The
mouse was then removed and placed in a clean cage under the heat
lamp to await the next trial. Each mouse received 5 trials/day for 7
consecutive days, following this procedure. On day 8, the ﬁrst 2
trials were conducted in the usual manner. On the third trial, which
served as a probe trial, the platform was removed, and the mice
were allowed to swim for 60 seconds. The interval between trials 2
and the probe test (trial 3) was the same as for all other trials. Trials
4 and 5 followed the usual procedure with the submerged platform
returned to its location.
Two response measures were recorded for each trial of days
1e7dlatency and errors. The latencywas the time required to reach
and climb onto the platform, measured from when the mouse was
placed in the water. An error was counted each time the mouse
entered a zone not containing the platform, or when the mouse left
the zone that contained the platform without successfully
mounting it. If the mouse failed to ﬁnd the platform within
120 seconds, it was given an error score of 30 for that trial. On the
probe trial of day 8, the time spent in the zone that normally con-
tained the platform was the measure of interest.
2.2.2. Nonmatching-to-sample
The stimuli for the sample and test trials were black and white
cylinders (30 cm long  3 cm in diameter), suspended 5 cm above
the surface of the water. The position of the cylinders was
controlled manually by the experimenter through a system of
pulleys, weights, and wires that ran inconspicuously outside the
perimeter of the pool and along the ceiling.
For each sample trial, the black or white cylinder was sus-
pended above the submerged platform. During the subsequent
test trial, both cylinders were present, but the cylinder that was
not present during the preceding sample trial was suspended over
the platform and cued its location. Thus, if on a given sample trial,
the black cylinder signaled the location of the platform then, on
the succeeding test trial, the white cylinder signaled its location.
The locations of the cylinder and platform varied between sample
trials. The black or white cylinder was selected as the sample
stimulus for each pair of trials according to a semi-random
schedule that ensured that each cylinder was the sample for 50%
of the trials. For each test trial, the platformwas moved to another
zone with the non-sample cylinder located directly above it. The
sample stimulus was also moved to a different zone. The zone that
contained the submerged platformwas changed after each sample
and test trial, according to a random schedule, to eliminate the use
of spatial cues. All zones were used equally for locating cues in the
sample and test trials and, within the zones, the platform was
positioned randomly.
NMTS testing began 10 days after the completion of the spatial
memory test. At the beginning of each sample trial, the mouse was
placed in the pool at the same location (south-east zone), facing the
wall of the pool, and allowed to swim to the submerged platform
under the sample cylinder. Themouse remained on the platform for
20 seconds. The mouse was then removed and placed in a clean
cage under the heat lamp while the platform was moved and the
cylinders put in position for the test trial. The organization of the
cylinders and platform took about 10 seconds. The mouse was then
placed in the pool at the usual location and allowed to swim to the
submerged platform or until 60 seconds had elapsed.The time required to reach and climb onto the platform (latency)
was recorded. An error was counted each time the mouse entered a
zone not containing the platform, or when the mouse left the zone
that contained the platformwithout successfully mounting it. If the
mouse failed to ﬁnd the platformwithin 60 seconds, it was given an
error score of 15 for that trial. In either case, the mouse was allowed
10 seconds on the platform before being returned to a holding cage
under the heat lamp, to await the next pair of trials. The mice were
tested in squads of 4 or 5, which allowed for an interval of
4e5 minutes between each pair of trials. Ten daily sessions, each
consisting of 5 pairs of sample and test trials, were administered.
Latency and error scores for each sample and test trial were
recorded.
2.2.3. Brightness discrimination learning
The discrimination learning taskwas administered 2weeks after
the NMTS task. In this test, mice learned to discriminate between
the black and white arms of the T-maze. For half the mice, the black
armwas positive with the submerged platform located at the end of
that arm; for the other half, the white arm was positive. The posi-
tion of the panels was determined by a random schedule. At the
beginning of each trial, the mouse was placed in the stem at the
edge of the pool and allowed to ﬁnd and mount the submerged
platform. Each mouse received 20 daily sessions of 5 trials/day until
a criterion of 8 of 10 errorless trials over 2 consecutive days was
achieved. An error was scored each time a mouse’s entire body
entered the incorrect arm and when a mouse left the correct arm
after having entered it. Mice were scored on the number of trials
required to reach criterion with individuals that did not reach the
criterion by day 20 being assigned a score of 100. Latency to plat-
form on each trial was also recorded.
2.3. Genotyping by polymerase chain reaction
Tail clippingswere digested overnight at 55 C by proteinase K and
cell lysis buffer (Cell Signaling Technology, Danvers, MA, USA). DNA
was extracted using phenol followed by precipitation and washing
with ethanol. DNAwas resuspended in 25 mL of Tris-EDTA buffer, and
aliquots were ampliﬁed by polymerase chain reaction (PCR) using
primers for the APP transgene (50-AGAAATGAAGAAACGCCAAGCGC-
CGTGACT-30 and 50-TGTCCAAGATGCAGCAGAACGGCTACGAAAA-30).
Each 25 mL PCR contained 0.3 mM deoxyribonucleotide mix (Fer-
mentas, R0192), 1.5 mM of magnesium chloride, and 1.25 units of
Platinum Taq DNA polymerasewith its buffer (Invitrogen,10966-018).
The thermocycler program consisted of a period of 3 minutes at 94 C
followed by 30 repeated cycles of 20 seconds at 94 C, 20 seconds at
68 C, and 90 seconds at 72 C. Following these repeated cycles, the
program completed with 7 minutes at 72 C. The ampliﬁed PCR
productswere run through a 2% agarose gel containing SYBR safe DNA
Gel Stain (Invitrogen, S33102) and visualized using the Fluorochem
image system (Model 8000, Alpha Innotech Corp, San Leandro, CA,
USA).
2.4. Hippocampal gene expression analysis (quantitative reverse
real-time PCR)
Total RNA was isolated and puriﬁed from hippocampi using the
Trizol method (Life Technologies, Carlsbad, CA, USA) and RNeasy
mini kit (Qiagen, Venlo, the Netherlands) according to the manu-
facturers’ instructions. RNA purity and quantity were assessed by
using a NanoDrop 1000 (NanoDrop Technologies, Wilmington, DE,
USA) to measure the 260 nme280 nm UV absorbance ratio and
260 nm absorbance, respectively. One microgram of total RNA was
reverse transcribed into complementary DNA using a High-
Capacity cDNA Reverse Transcription kit (Life Technologies).
Fig. 1. (A) During spatial memory acquisition, transgenic mice receiving the WFD performed even worse than transgenic mice on the control diet. There were no differences ac-
cording to diet in the wild-type mice. Performance by groups not sharing a letter differs over the entire testing period. A similar pattern of statistically signiﬁcant and nonsigniﬁcant
differences is seen when errors are analyzed (Supplementary Fig. 1). (B) In the probe trial, transgenic mice performed worse than wild type, n ¼ 8e10/group. All data mean  SEM.
Abbreviations: Con, control diet; SEM, standard error of the mean; Tg, transgenic; WFD, whole-food diet; Wt, wild type.
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Expression Master Mix and TaqMan Gene Expression Assays on an
ABI Prism 7000 SDS system (Life Technologies). Assays were
selected to target markers of insulin signaling and inﬂammation
(Supplementary Table 2). Relative differences in gene expression
were quantiﬁed by using the DDCT method to calculate fold change
values between treatments (Livak and Schmittgen, 2001). Wild-
type mice on the control diet acted as the reference group, and
expression was normalized by the average CT of 2 endogenous
control genes (18S, GAPDH).
2.5. Cortical Ab burden
Cortices from transgenic mice were homogenized in buffered
sucrose solution followed by either a mixture of 0.4% diethylamine
and 100mMNaCl for soluble Ab or cold formic acid for the isolation
of total Ab. After neutralization, diluted samples were analyzed for
Ab40 and 42 using commercially available sandwich ELISA kits
(BioSource, Burlington, Ontario, Canada) according to the manu-
facturer’s instructions, and as performed previously (McLaurin
et al., 2006).
2.6. Statistical analysis
The variables analyzed for the spatial memory acquisition,
NMTS, and discrimination learning tests were the latency (in sec-
onds) and the number of errors exhibited on each trial across all
testing days. Only latencies are presented in the main text, as the
latency and error scores yielded the same pattern of statistically
signiﬁcant and nonsigniﬁcant differences for all tests; error scores
are provided in Supplementary Figures. The variable of interest for
the spatial probe trials was the amount of time spent in the plat-
form zone.
Linear mixed models (PROC MIXED; SAS v9.3) with an autore-
gressive covariance structure were used to test the differences be-
tween groups on behavioral measures that involved repeated
measures. The ﬁxed effect of trials was assessed to indicatewhether
mice exhibited signiﬁcant improvements on the respective tasks
with practice. The generalizability of such improvement was
assessed by testing for “trials  diet,” “trials  transgene,” and
“trials  diet  transgene” interactions. If these interactions were
not statistically signiﬁcant (p > 0.05), any practice effects were
considered to be comparable across experimental groups. The ﬁxed
effects of diet, transgene, and their interaction were tested as the
primary outcomes. Statistically signiﬁcant (p < 0.05) “diet 
transgene” interactions were decomposed by testing for differencesbetween the 4 experimental groups using Tukey post hoc test to
adjust for multiple comparisons. A similar approach was taken
when analyzing the probe trial, gene expression, and cortical Ab
data except that the ﬁxed effects were tested in a general linear
model (PROC GLM).
Of the 39 mice transferred for cognitive testing, 7 mice prema-
turely died (6 transgenic/1 wild type; 5 control diet/2 whole-food
diet). Mice were excluded from the statistical analysis of the
cognitive test during which they died. Accelerated mortality is a
characteristic of the TgCRND8 mouse line that is shared by humans
with AD (Chishti et al., 2001).
3. Results
Mice on the WFD were heavier than those on the control diet at
death (p ¼ 0.021) (Supplementary Table 3). Total per capita con-
sumption by mice on the WFD appeared somewhat higher than
mice on the control diet during the same 2-week period (31 g/
mouse/wk vs. 28 g/mouse/wk). Group housing prevented mea-
surement of food intake at an individual level, and therefore, the
use of inferential statistics.
3.1. Cognitive function
3.1.1. Spatial memory
During the acquisition stage which reﬂects spatial learning and
memory, there was a signiﬁcant main effect of trials (p < 0.01)
which showed no interaction with either diet (p ¼ 0.66), transgene
(p ¼ 0.47), or diet and transgene (p ¼ 0.53) indicating comparable
improvement by all groups with practice. Nevertheless, there was a
“diet  transgene” interaction (p < 0.01; Fig. 1A) such that trans-
genic animals exhibited longer latencies over the testing period
than the wild-type mice, but the Tg-WFD group took even longer
than the Tg-Con group to ﬁnd the platform. Therewas no difference
in performance according to diet in wild-type animals. A similar
pattern of statistically signiﬁcant and nonsigniﬁcant differences
was found when errors were analyzed (Supplementary Fig. 1).
During the probe trial test of spatial memory, this interaction was
not observed (p ¼ 0.99), and there was no main effect of diet (p ¼
0.29). However, transgenic animals spent less time in the platform
zone than the wild-type mice (p ¼ 0.024; Fig. 1B).
3.1.2. Nonmatching-to-sample
There was a signiﬁcant main effect of trials (p ¼ 0.036) which
showed no interaction with either diet (p ¼ 0.34), transgene (p ¼ 0.56),
or diet and transgene (p¼ 0.78), indicating comparable improvement by
Fig. 2. In the NMTS test, transgenic mice receiving the WFD performed even worse
than transgenic mice on the control diet. There were no differences according to diet in
the wild-type mice. Performance by groups not sharing a letter is statistically different
over the entire testing period. A similar pattern of statistically signiﬁcant and
nonsigniﬁcant differences is seen when errors are analyzed (Supplementary Fig. 2), n ¼
8e10/group. All data mean  SEM. Abbreviations: Con, control diet; NMTS,
nonmatching-to-sample; SEM, standard error of the mean; Tg, transgenic; WFD,
whole-food diet; Wt, wild type.
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Fig. 2) revealed that transgenic animals exhibited longer latencies over
the testing period than the wild-type mice, but the Tg-WFD group took
even longer than the Tg-Con group to ﬁnd the platform. There was no
signiﬁcant difference in performance according to diet in wild-type
animals. A similar pattern of statistically signiﬁcant and nonsigniﬁcant
differences were found when errors were analyzed (Supplementary
Fig. 2).
3.1.3. Brightness discrimination learning
Transgenic mice required more trials to reach criterion (p ¼ 0.025;
Supplementary Table 4), exhibited longer latency to platform per trial
(p ¼ 0.011) and made more errors per trial (p < 0.01) than wild-type
mice. There were no statistically signiﬁcant effects of diet (p ¼ 0.19;
p ¼ 0.67; p ¼ 0.18) or a “diet  transgene” interaction (p ¼ 0.53; p ¼
0.45; and p¼ 0.48) for trials-to-criterion, latency, or errors, respectively.
3.2. Gene expression
Transgenic animals exhibited higher expression of the astro-
cyte marker glial ﬁbrillary acidic protein (GFAP; p < 0.01), as well
as lower expression of the insulin-signaling associated genes
mitogen activated protein kinase-1 (MAPK1; p ¼ 0.018) and
glycogen synthase kinase-3 alpha (GSK3A; p ¼ 0.049) (Fig. 3). A
signiﬁcant “diet  transgene” interaction was observed for the
proinﬂammatory cytokine tumor necrosis factor-alpha (p ¼
0.013; TNFA) such that the Tg-WFD group exhibited the higher
expression than all other groups which did not signiﬁcantly
differ from each other (Fig. 3). No signiﬁcant differences in
expression were observed for the remaining target genes
(Supplementary Fig 3).
3.3. Cortical Ab
Among the transgenic animals, there were no signiﬁcant dif-
ferences between diet groups on any of the measures of Ab burden
(Supplementary Table 5).4. Discussion
The impaired performance of the Tg-CON group on the behav-
ioral tasks is consistent with similar reports of cognitive deﬁcits in
this transgenic model of AD (Romberg et al., 2013). The unexpected
ﬁnding was that transgenic mice fed the WFD were even more
impaired on the spatial memory and NMTS tasks. We initially
predicted that the WFD would ameliorate behavioral deﬁcits by
enhancing brain insulin signaling and reducing neuroinﬂammation.
In fact, the results indicate that an interaction between transgene
driven Ab deposition and the WFD produced a heightened neuro-
inﬂammatory response that coincided with exacerbation of be-
havioral deﬁcits.
The behavioral tasks selected for this study assessed various
aspects of learning and memory, which can be dissociated and
linked to different brain regions. The spatial memory test, as
measured in theMorris water maze, is a form of context-dependent
reference memory that depends on the functional integrity of the
hippocampus (Morris, 1984). The NMTS conditional rule-learning
task, because of the inherent strategic and working memory com-
ponents, is identiﬁed with frontal lobe function (Moscovitch and
Winocur, 1995). The brightness discrimination task assesses non-
conditional learning that is believed to depend on striatal struc-
tures (McDonald et al., 1999). In AD, hippocampal, frontal lobe, and
striatal functions are compromised to varying degrees. The deﬁcits
of transgenic mice on all tasks are consistent with this pattern and
support the use of this transgenic strain as a model of AD. Further,
the ﬁnding that WFD impaired performance on the spatial memory
and NMTS tasks, but not the brightness discrimination task, pro-
vides insight into brain mechanisms that were susceptible to di-
etary effects.
We did not collect data on swimming speed or path length, and
therefore, cannot absolutely exclude the possibility that motor
impairments contributed to the observed differences in perfor-
mance. The question arises as to whether impairment in the ability
to detect crucial environmental stimuli or perform the appropriate
swimming behavior could account for observed deﬁcits on the
various tasks. This interpretation receives some support from the
relatively poor early performance of the transgenic groups on the
spatial memory and NMTS tasks. However, this effect has been
observed in a previous work with other impaired mouse models
(Winocur et al., 2006) and attributed to initial disorientation related
to the animals’ cognitive impairment. Several lines of evidence in
the present study also argue against a performance deﬁcit inter-
pretation. First, analysis of latency and error data yielded the same
overall pattern of statistically signiﬁcant and nonsigniﬁcant differ-
ences in performance for all tests. Because the number of errors
made in reaching the platform reﬂects disorganized swimming
patterns indicative of cognitive dysfunction, their agreement with
latency data suggests that differences in performance did not
merely reﬂect impairments in mobility. Second, latency to platform
in the brightness discrimination test did not differ by diet or exhibit
a statistically signiﬁcant “diet  transgene” interaction. If WFD-
induced deﬁcits in performance on the spatial memory and NMTS
tests were entirely the result of motor impairments, a similar
“diet  transgene” interaction should also be observed on the
brightness discrimination test as a generalized motor impairment
would be expected to manifest itself across all tasks. Furthermore,
similar performance of the Tg-WFD and Tg-Con groups on the
brightness discrimination task argues against a deleterious effect of
the WFD on visual acuity. Finally, the mice exhibited statistically
signiﬁcant improvements in performance with practice (“trials”),
which did not appear to be dependent on genotype or diet for the
acquisition phase of the spatial memory test, and transgenic mice
subsequently performed similarly on the probe trial regardless of
Fig. 3. Hippocampal gene expression of mitogen activated protein kinase-1 (MAPK1; panel A) and glycogen synthase kinase-3a (GSK3A; panel B) were signiﬁcantly lower in
transgenic mice compared with the wild-type mice. Transgenic mice exhibited higher expression of glial ﬁbrillary acidic protein (GFAP; panel C) compared with wild type.
Transgenic mice receiving the WFD exhibited higher tumor necrosis factor-a expression compared with all other treatment groups which did not differ from each other (TNFA; panel
D; bars not sharing a letter are statistically different), n ¼ 5 independent samples/group. All data mean  SEM. Abbreviations: Con, control diet; SEM, standard error of the mean; Tg,
transgenic; TNFA, tumor necrosis factor-alpha; WFD, whole-food diet; Wt, wild type.
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impaired in ﬁnding the platform’s location during training; how-
ever, once the locationwas learned the Tg-WFD and Tg-CON groups
remembered it and had no trouble using relevant cues to swim in
the appropriate zone of the maze. These results further suggest
intact sensorimotor function as it is unlikely that a motor impair-
ment would improve with practice, and that the WFD would
adversely inﬂuence visual acuity throughout testing without also
inﬂuencing performance on the probe trial.
Group differences in cognitive function did not match differences
in body weight, and the WFD did not seem to adversely inﬂuence
food intake or body weight. Great care was taken to ensure that the
WFD met established guidelines for nutritional adequacy (Reeves
et al., 1993). It could be argued that the WFD represents a more
“natural” mouse diet compared with most laboratory diets as feral
mice are opportunistic omnivores that, depending on availability,
frequently consume vegetation and large amounts of animal protein
(Houtcooper, 1978; Landry, 1970; Tann et al., 1993). Therefore, it
seems unlikely that WFD-induced impairment of cognitive function
was related to generalized toxicity or pervasive physical illness.
Cerebral insulin signaling and neuroinﬂammation are considered
to play an interconnected role in AD pathogenesis (Bomﬁm et al.,
2012; Craft et al., 2013; de la Monte, 2012; Talbot et al., 2012) and
were important mechanisms of interest in this study. Although
changes in whole-body insulin sensitivity were not assessed, simi-
larities in macronutrient distribution and energy density make large
diet-induced differences in insulin sensitivity unlikely.We found that
transgenic animals exhibited reduced hippocampal gene expression
of MAPK1 which is part of an insulin receptor substrate-1 indepen-
dent insulin signaling pathway that is dysregulated in AD (Hallock
and Thomas, 2012; Khan and Alkon, 2006; Talbot et al., 2012;
Veeranna et al., 2004) and appears critically important for learning,
memory, and synaptic plasticity (Nelson et al., 2008; Sweatt, 2004).Thisﬁnding is consistentwith another study involving TgCRND8mice
that found less hippocampal activation of MAPK1 both in basal con-
ditions and under cholinergic stimulation (Giovannini et al., 2008).
We also observed that transgenic animals exhibited lower expression
of GSK3A, which has been associated with cognitive impairments in
animals (Maurin et al., 2013). Therefore, aberrant signaling through
the MAPK1 and GSK3A pathways may have contributed to impaired
performance by the transgenic animals on every behavioral test in
this study. However, they did not appear to coincide with exacerba-
tion of these behavioral deﬁcits by the WFD on certain tasks.
A more robust neuroinﬂammatory response in animals on the
WFD, as determined by greater expression of an overlapping set of
neuroinﬂammatory genes, bettermatched the pattern of exacerbated
behavioral deﬁcits. Compared with their wild-type littermates,
transgenic animals exhibited higher expression of GFAP, a marker of
astrocyte activation, which agrees with studies identifying reactive
astrocytes as an early event in the TgCRND8 mouse (Dudal et al.,
2004) that is shared with human AD (Robinson et al., 1994). High
GFAP expression has also been shown to be inversely related to
cognitive function (Kashon et al., 2004), and to coincide with
impaired brain insulin-signaling (Rivera et al., 2005) which agrees
with our ﬁndings of reduced MAPK1 and GSK3A expression by the
transgenic animals. More importantly, the transgenic animals on
the WFD exhibited the highest TNFA expression in conjunction with
the poorest performance on tests of spatial learning and strategic rule
learning. Increased expression of TNFA has been linked to AD path-
ogenesis (Tarkowski et al., 2003) and cognitive dysfunction in AD
animal models (Gabbita et al., 2012; Medeiros et al., 2007; Tweedie
et al., 2012). Thus, combined elevation of GFAP and TNFA seems to
distinguish the Tg-WFD from the Tg-Con group which only exhibited
increased expression of GFAP.
Exacerbated behavioral deﬁcits and elevated TNFA expression did
not coincidewith differences in the deposition of soluble or insoluble
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responsible for this ﬁnding. First, glial activation has been linked to
phagocytic Ab clearance in AD mouse models overexpressing proin-
ﬂammatory cytokines including TNFA (Chakrabarty et al., 2010, 2011;
Shaftel et al., 2007). Interestingly, inADmousemodels improvements
in behavior associated with TNFA inhibition have occurred both with
(Tweedie et al., 2012) and without (Gabbita et al., 2012) any impacts
on Ab pathology. These studies suggest that activated glia may limit
Ab deposition even as production of potentially disruptive substances
for behavior, like TNFA, are elevated. Second, we did not measure the
abundance of Aßoligomers,whichmay bemore proximally related to
producing neuroinﬂammatory and insulin resistant brain states.
Interestingly, behavioral beneﬁts of dietary antioxidants (Harrison
et al., 2009; Quinn et al., 2007), blueberries (Joseph et al., 2003),
and an insulin-sensitizing drug (Denner et al., 2012) have occurred
without any effects on Ab deposition in animal models.
The combined administration of multiple whole foods precludes
conclusions as to which speciﬁc dietary component is responsible
for promoting neuroinﬂammation and behavioral dysfunction in
the TgCRND8 mouse. It is clear that this synergistic effect reﬂected
the adverse interaction of the WFD with transgene-driven Ab
deposition. The WFD differed from the control diet in its inclusion
of freeze-dried salmon, vegetables, fruits, and smaller amounts of
other botanicals. We propose that Ab impaired the normally
adaptive cellular response to the phytochemicals contained in this
complex mixture. This hypothesis is based on the capacity of many
food-borne phytochemicals to activate cellular stress response
pathways, partly because of their direct prooxidant effects, that
serve to upregulate endogenous antioxidant defense systems
(Calabrese et al., 2012; Son et al., 2008). The beneﬁt of this indirect
antioxidant action, or hormetic effect, derives from the ability of
low-level oxidative stress to precondition cells so that they are
better prepared when larger insults strike (Mattson, 2008). How-
ever, such beneﬁts assume unimpaired activation of stress response
pathways and downstream antioxidant defense systems. Interest-
ingly, activation of the phytochemical-sensitive nuclear factor
erythroid-2 p45-related factor 2 and/or antioxidant response
element stress response pathway has been shown to involve
several insulin signaling molecules (Son et al., 2008; Wang et al.,
2012; Wu et al., 2006; Yu et al., 1999) that have been shown to be
downregulated in human AD and AD animal models including in
this study (Bomﬁm et al., 2012; Chua et al., 2012; Ma et al., 2009;
Maesako et al., 2012; Rivera et al., 2005; Talbot et al., 2012).
Furthermore, damage to small molecule antioxidants like gluta-
thione and reduced activity of enzymes that participate in certain
cellular antioxidant defenses are seen in human AD and animal
models of Ab deposition (Anantharaman et al., 2006; Cristalli et al.,
2012; Garg et al., 2011; Ghosh et al., 2012; Kharrazi et al., 2008; Lee
et al., 2012a; Puertas et al., 2012; Schuessel et al., 2005; Soﬁc et al.,
2006). The unintended consequence of combining sustained
exposure to phytochemicals with Ab-related dysregulation in
cellular responses may be the promotion of oxidative stress.
Because oxidative stress can regulate Ab-cytotoxicity and tran-
scription of proinﬂammatory cytokines, it may explain the adverse
behavioral impact of the WFD (Kaltschmidt et al., 1997; Shi and
Gibson, 2007). This framework agrees with ﬁndings of elevated
TNFA expression in transgenic animals receiving the WFD without
such an effect in wild-type mice, or transgenic mice receiving the
control diet, that presumably had intact cellular response systems
or were not exposed to similarly high amounts of phytochemicals,
respectively. Epidemiologic studies have generally indicated that
dietary phytochemical consumption is related to better cognitive
function and reduced incidence of dementia (Commenges et al.,
2000; Devore et al., 2012; Kesse-Guyot et al., 2012). However, one
study found that certain phytochemical subclasses exerted positiveor null effects on episodic memory but were negatively associated
with executive function (Kesse-Guyot et al., 2012). This domain-
speciﬁc effect resembled our results in which frontal lobe-
dependent strategic rule learning was further impaired in
transgenic mice on the WFD, but there was no such effect on the
highly hippocampus-dependent spatial memory probe.
Our results highlight the importance of better understanding
the role that global diet quality may play in moderating single
nutrient effects. Some of the main components of the whole-food
diet included blueberries (Joseph et al., 1999, 2003; Shih et al.,
2010), spinach (Joseph et al., 1999), and DHA (Arsenault et al.,
2011; Calon et al., 2004), which have been shown to beneﬁcially
inﬂuence cognitive function in animal models of aging or AD when
administered as extracts. However, when combined together in this
study they adversely affected some behavioral outcomes. These
ﬁndings contrast with studies in which combining DHA with
polyphenolic compounds (Giunta et al., 2010; Ma et al., 2009)
seemed to elicit greater beneﬁts than either alone on behavior and
Ab deposition in the Tg2576 mouse. However, not all dietary
combinations have proven beneﬁcial. Coadministration of vitamins
E and C to APP/PS1 mice resulted in spatial memory impairments
that were not seen when vitamin C was administered alone
(Harrison et al., 2009). In a similar mouse model, combining DHA
with phospholipid precursors exacerbated Ab deposition compared
with either separately whereas coadministering both these com-
pounds with additional micronutrients produced an anti-
amyloidogenic effect (Broersen et al., 2013). Combining DHA with
a high saturated fat mixture appeared to promote amyloidogenic
processing and abolished the anti-amyloidogenic effect of DHA in
the TgCRND8 mouse (Amtul et al., 2011). Collectively, these studies
indicate that dietary effects may reﬂect the interaction between
single dietary components, and that these combinations can
sometimes produce unexpected results.
It is unclear whether the impact of the WFD on behavior and
gene expression is because of the composite effect of the entire diet
or related to the relative abundance of a particular dietary
component. For instance, past studies have found behavioral ben-
eﬁts to the administration of berry extracts in AD mouse models
(Joseph et al., 2003; Shih et al., 2010). However, the WFD in this
study also contained relatively large amounts of cruciferous vege-
tables (kale, cabbage, broccoli, brussel sprouts, and radishes) which
are a rich source of glucosinolate phytochemicals. Glucosinolate
exposure has been shown to generate reactive oxygen species in
animal models (Valgimigli and Iori, 2009), which may underlie
their chemopreventative activity in cancer cells (Singh and Singh,
2012). If such prooxidant effects apply to brain tissue undergoing
active Ab deposition that would support our hypothesis that
chronic exposure to large amounts of phytochemicals may underlie
the cognitive deﬁcits and neuroinﬂammatory gene expression
associated with WFD consumption by the transgenic animals. In
terms of comparative dosages, the dietary concentration of DHA
was lower than studies which have observed positive (Calon et al.,
2004; Ma et al., 2009) and null (Arendash et al., 2007) effects on
behavior in AD mouse models but comparable to another in which
DHA exerted beneﬁcial inﬂuences on electrophysiological and
behavioral outcomes (Arsenault et al., 2011). The dietary concen-
tration of phytochemicals, as assessed by total polyphenol content
(Shih et al., 2010), and dietary antioxidant capacity (Joseph et al.,
2003) appear higher than other studies in AD mouse models.
However, this was by design as other studies used puriﬁed extracts
or compounds which may have had higher bioavailability and
would not have been subject to food-food interactions (Spencer
et al., 2008). The dosage of dietary bioactives in this study were
most likely higher than could be reasonably attained from non-
supplemental sources in the human diet, and there is always the
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in human subjects. However, such limitations apply to most dietary
studies in AD mouse models with implications that are beyond the
scope of this article. It was not our intent to use this study to
develop speciﬁc recommendations, but to test a novel hypothesis
based on supporting observational evidence with relevance to hu-
man health. Future attempts to determine the relative importance
of speciﬁc dietary components versus their dosage may be
informative.
In conclusion, a whole-food diet based on the epidemiologic
literature exacerbated cognitive dysfunction in a mouse model of
familial AD possibly by enhancing neuroinﬂammation. These un-
expected results highlight the potential complexity of food-food
interactions and the potentially unexpected ways in which diet
may inﬂuence AD progression. We feel this study supports those
who caution against high dose supplemental consumption of
phytochemicals and promote the need to better assess the safety
proﬁle of food-borne compounds (Egert and Rimbach, 2011). Such
caution seems warranted, as individuals with cognitive impair-
ments have been shown to be interested consumers of herbal
remedies and supplements which are widely perceived to be
harmless by elderly people (Dergal et al., 2002; Shahrokh et al.,
2005).
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